Memory Lapses During Menopause: What Could Be Causing It?

How Common Are Memory Lapses During Menopause?

Memory complaints are one of the most frequently reported, and frequently dismissed, symptoms of the menopause transition. In the Study of Women's Health Across the Nation (SWAN), up to 62% of women in perimenopause reported noticeable difficulties with memory and concentration. That figure makes cognitive symptoms nearly as prevalent as hot flashes in the same population.

The complaints are specific. Women most often describe:

• Losing a word mid-sentence ("tip of the tongue" moments)
• Walking into a room and forgetting why
• Difficulty concentrating on reading or multi-step tasks
• Slowed processing when tired or after a poor night of sleep

These are not imagined. Objective neuropsychological testing conducted in the Penn Ovarian Aging Study confirmed measurable declines in verbal memory scores during perimenopause, independent of mood or sleep disruption.

Does This Mean You Are at Risk for Dementia?

No. Perimenopause-related cognitive changes are distinct from early dementia. The SWAN cognitive substudy found that verbal memory scores returned toward premenopausal baseline after women reached postmenopause and hormonal levels stabilized. That trajectory is reassuring and is fundamentally different from the progressive decline seen in Alzheimer's disease.

What distinguishes normal menopausal forgetfulness from a warning sign:

| Menopausal brain fog | Red flag requiring evaluation | |---|---| | Forgetting a word, then recalling it later | Forgetting what a common object is used for | | Losing your train of thought in conversation | Repeated disorientation in familiar places | | Slower recall when fatigued | Personality or behavior changes noticed by others | | Misplacing keys | Getting lost driving a familiar route |

If you recognize anything in the right column, ask your clinician for a formal cognitive screen. The Alzheimer's Association recommends that any concern about progressive memory loss be evaluated with standardized tools such as the MoCA (Montreal Cognitive Assessment).

Why Does Estrogen Decline Affect Memory?

Estrogen is not only a reproductive hormone. Estradiol receptors are distributed throughout the brain, with the highest concentrations in the hippocampus (the brain's memory-encoding center), the prefrontal cortex (attention and executive function), and the amygdala (emotional memory). When estradiol falls during perimenopause, these regions lose a key signaling input.

Estrogen's Role in Hippocampal Function

Estradiol promotes synaptogenesis (the formation of new synaptic connections) and supports acetylcholine release, a neurotransmitter critical for encoding new memories. Preclinical and human neuroimaging studies show that lower estradiol levels correlate with reduced hippocampal activation during verbal memory tasks.

The Cholinergic Connection

The brain's cholinergic system, which relies on acetylcholine to consolidate short-term into long-term memory, is estrogen-sensitive. Research published in Menopause found that estrogen withdrawal reduces choline acetyltransferase activity in the basal forebrain, the same system targeted by Alzheimer's drugs. This is a mechanistic link, not a diagnosis. It explains why the functional complaint feels real even when standard memory tests show only mild change.

The Prefrontal Cortex and "Fuzzy Thinking"

The prefrontal cortex governs working memory and attention. Women in perimenopause frequently report difficulty holding multiple pieces of information in mind at once, the sensation of mental "fuzziness." Functional MRI studies show altered prefrontal activation patterns during perimenopausal estradiol fluctuation, which normalize in postmenopause.

Other Causes That Amplify Menopausal Memory Problems

Estrogen decline is the primary hormonal driver, but it rarely acts alone. Several co-occurring conditions common during perimenopause and postmenopause compound the cognitive impact significantly.

Sleep Disruption

This is the most clinically underappreciated contributor. Memory consolidation happens during slow-wave and REM sleep. Hot flashes fragment sleep architecture, and a 2018 analysis in the journal Sleep Medicine found that each additional night-sweat-related arousal was independently associated with worse next-day verbal recall. You cannot consolidate memories you never slept through.

Treating night sweats can produce a measurable cognitive benefit even before any direct cognitive intervention.

Depression and Anxiety

Perimenopause carries a substantially elevated risk of new-onset depressive episodes. ACOG Practice Bulletin No. 141 acknowledges the bidirectional relationship between mood symptoms and cognitive complaints during the transition. Depression independently impairs memory encoding, attention, and processing speed. Anxiety floods working memory with intrusive worry, leaving less cognitive bandwidth for the task at hand.

The practical implication: if you are also low in mood, tearful, or persistently anxious, treating mood symptoms first often produces noticeable cognitive improvement.

Thyroid Dysfunction

Hypothyroidism causes forgetfulness, slowed thinking, and word-finding difficulties that are clinically indistinguishable from menopausal brain fog. The conditions share a demographic. The American Thyroid Association estimates that 1 in 8 women will develop a thyroid disorder in her lifetime, with peak incidence in the perimenopausal decade. Subclinical hypothyroidism (elevated TSH with normal T4) is especially easy to miss and is common after age 40.

Any woman presenting with memory complaints during perimenopause should have a TSH checked. This is not optional.

Vitamin B12 Deficiency

B12 is required for myelin synthesis and neuronal signaling. Deficiency causes a progressive picture of forgetfulness, slowed processing, and tingling in extremities. Risk increases with age, proton pump inhibitor use (common in midlife women for reflux), metformin use (common in PCOS and prediabetes), and a vegetarian or vegan diet. A serum B12 below 300 pg/mL warrants supplementation even before frank deficiency is confirmed.

Iron Deficiency

Iron deficiency without anemia causes cognitive fatigue and poor concentration, particularly in women who still have heavy perimenopausal periods. Research in the British Journal of Nutrition found that iron supplementation in iron-depleted but non-anemic women improved cognitive performance scores. Ferritin below 30 mcg/L in a woman with memory complaints and heavy bleeding is clinically significant.

Alcohol and Medications

Benzodiazepines, anticholinergic drugs (certain antihistamines, bladder medications, some antidepressants), and sleep aids accumulate more readily in women than men due to lower lean body mass and slower hepatic metabolism. Alcohol disrupts REM sleep and is directly neurotoxic with regular use. A medication review should be part of every cognitive symptom workup.

Cardiovascular Risk Factors

Uncontrolled hypertension, insulin resistance, and elevated LDL cholesterol all impair cerebrovascular perfusion and worsen cognitive reserve over time. The menopause transition accelerates cardiovascular risk in women, and the American Heart Association's 2020 statement explicitly names menopause as a female-specific cardiovascular risk factor that clinicians should assess. Managing metabolic health is also cognitive health management.

Life Stage Matters: How the Timing of Menopause Changes the Picture

Not all menopause is the same, and the cognitive impact differs meaningfully by how and when the transition occurs.

Natural Perimenopause (Typical Age 45-55)

Cognitive symptoms usually begin during late perimenopause when estradiol fluctuation is most erratic. Irregular cycles, vasomotor symptoms, and sleep disruption all converge. The SWAN cognitive data show that this stage is the window of greatest reported impairment, but also the window most likely to improve spontaneously.

Surgical Menopause (Bilateral Oophorectomy)

Women who undergo bilateral oophorectomy before natural menopause experience an abrupt drop in estradiol rather than the gradual decline over 4-8 years seen in natural menopause. A landmark Mayo Clinic study found that women who underwent bilateral oophorectomy before age 46 and did not receive hormone therapy had a significantly higher risk of cognitive impairment and dementia later in life compared to women who underwent natural menopause. If you have had your ovaries removed before your natural menopause age and are not on hormone therapy, discuss this explicitly with your clinician.

Premature Ovarian Insufficiency (POI, Before Age 40)

Women with POI face decades of estrogen deficiency. Cognitive risk with POI is not well characterized in large RCTs because the population is smaller, but ACOG and the European Society of Human Reproduction and Embryology both recommend hormone therapy until at least the average age of natural menopause (51) to protect neurological, cardiovascular, and bone health.

Reproductive Years: PCOS and Hormonal Contraception

Women with PCOS have higher rates of insulin resistance and androgen excess, both of which may independently affect cognitive function. The cognitive effects of hormonal contraception in reproductive-age women are a separate and contested research question. Some progestin-containing methods have been associated with subjective cognitive complaints in individual studies, but no consistent signal has emerged in systematic reviews.

Postmenopause

After the transition stabilizes, most women notice that the acute fogginess of perimenopause improves. Ongoing cognitive health in postmenopause depends more on sleep, metabolic health, physical activity, and social engagement than on hormone levels alone.

Does Hormone Therapy Help Memory?

This is the most clinically contested question in menopause cognitive medicine, and the honest answer is: it depends heavily on timing.

The "critical window" or "timing hypothesis" holds that hormone therapy (HT) may support cognitive function when started close to menopause but could be neutral or even modestly harmful when started a decade or more after menopause. This hypothesis is derived primarily from:

• The Women's Health Initiative Memory Study (WHIMS), which enrolled women aged 65-79 and found that conjugated equine estrogen plus medroxyprogesterone acetate increased dementia risk. The average age at enrollment was 71, meaning most women were more than 10 years past menopause.
• The SWAN cognitive substudy and several observational cohorts that suggest better cognitive outcomes in women who initiate HT within a few years of their final menstrual period.

The Menopause Society's 2023 position statement on hormone therapy does not recommend HT specifically to prevent or treat dementia, but acknowledges that for symptomatic women in early menopause, the overall benefit-risk profile is favorable. If vasomotor symptoms and poor sleep are driving your cognitive complaints, treating those symptoms with HT may produce indirect cognitive benefit.

The type of progestogen used may also matter. Micronized progesterone (Prometrium, generic) appears to have a more favorable neurological profile than medroxyprogesterone acetate (MPA) in observational data, though head-to-head RCT data in cognitive outcomes are limited.

What Else Can You Do? Practical, Evidence-Based Strategies

Prioritize Sleep as a Clinical Target

Targeting night sweats and improving sleep continuity produces cognitive gains that are measurable and rapid. Options include:

• HT for vasomotor-driven night sweats (see above)
• Cognitive behavioral therapy for insomnia (CBT-I): The American College of Physicians recommends CBT-I as the first-line treatment for chronic insomnia, ahead of medication. CBT-I is more effective than sleep medications at improving sleep architecture long-term.
• Non-hormonal options for night sweats: Fezolinetant (Veoza), FDA-approved in 2023 for moderate-to-severe vasomotor symptoms, and paroxetine 7.5 mg (Brisdelle) offer alternatives when HT is not appropriate.

Physical Exercise

Aerobic exercise is the single most replicated lifestyle intervention for brain health across the lifespan. A 2019 Cochrane review found that aerobic exercise improved cognitive function in adults over 50. Resistance training also improves executive function. The target is 150 minutes per week of moderate-intensity aerobic activity, with 2 sessions of resistance training, per CDC physical activity guidelines.

Blood Sugar and Insulin Resistance

The brain is highly glucose-dependent. Insulin resistance impairs the brain's ability to use glucose efficiently. Research published in the Journal of Clinical Endocrinology and Metabolism found that higher fasting insulin levels were associated with worse verbal memory scores in midlife women. A diet lower in refined carbohydrates, regular physical activity, and weight management all reduce insulin resistance and may support cognitive health.

Cognitive Engagement and Social Connection

No supplement replaces genuine cognitive challenge. Learning a new skill, engaging in complex reading, and maintaining close social relationships all build cognitive reserve. The data on "brain training" apps are mixed; the activity itself matters less than the novelty and social dimension.

Supplements: What the Evidence Actually Shows

• Omega-3 fatty acids (DHA/EPA): A 2012 Cochrane review found no benefit for cognition in older adults with normal baseline function. The picture may differ in those with actual omega-3 deficiency.
• Vitamin D: Low vitamin D is associated with cognitive decline in observational data, but RCT evidence for supplementation improving cognition is weak. Correcting frank deficiency (25-OH vitamin D below 20 ng/mL) is still clinically appropriate.
• Ginkgo biloba: The Ginkgo Evaluation of Memory (GEM) study found no benefit for dementia prevention in a large RCT. It is not recommended.
• Phosphatidylserine, lion's mane, and similar supplements: Evidence in menopausal women is insufficient to recommend.

Who Should See a Specialist?

Most women with menopause-related cognitive complaints do not need a neurologist. Your primary clinician or menopause specialist can address the large majority of causes. But refer or escalate in these situations:

• Cognitive complaints that interfere significantly with work, finances, or daily safety
• Rapid onset over weeks rather than months
• Family history of early-onset dementia with your own symptoms starting before 55
• Neurological symptoms accompanying memory changes (tremor, gait problems, visual disturbance)
• Formal cognitive screening (MoCA or MMSE) showing impairment below the expected threshold for age and education

The Hormone Therapy, Pregnancy, and Contraception Note

Memory-related treatments in menopause are not used in pregnancy, but a few points matter for women at the perimenopausal boundary.

Perimenopause does not equal infertility. Women can ovulate sporadically during the perimenopausal years. ACOG advises that women use contraception until 12 consecutive months without a period, confirming natural menopause. Hormone therapy used for menopausal symptoms is not a contraceptive. If you are perimenopausal and not certain you cannot conceive, a reliable contraceptive method should be used alongside any HT.

Fezolinetant (Veoza) carries a contraindication in pregnancy and should not be used by women who could become pregnant. FDA prescribing information for fezolinetant recommends pregnancy testing before initiation and reliable contraception during use.

Systemic hormone therapy (estradiol patches, pills, or sprays, plus a progestogen if the uterus is intact) is contraindicated in pregnancy. The risk category is not applicable in the usual sense because HT is prescribed only after menopause is confirmed, but any woman in early perimenopause who has not yet had 12 consecutive months of amenorrhea should ensure pregnancy is excluded before starting systemic HT.

Frequently Asked Questions